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Summary: 
Background: Despite the rising burden of chronic respiratory diseases, global data for lung 
function are not available. L We investigated global variation in lung function in healthy 
populations by region to establish whether regional1 factors contribute to lung function.                                                                                                                                                         
Methods: In an international, community-based prospective study, we enrolled individuals 
from communities in 17 countries between Jan 1, 2005, and Dec 31, 2009 (except for in 
Karnataka, India, where enrolment began on Jan 1, S 2003). Trained local staﬀ obtained data 
from participants with interview-based questionnaires, measured weight and height, and recorded 
forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC). We analysed data from 
participants 130–190 cm tall and aged 34–80 years who had a 5 pack-year smoking history or 
less, who were not aﬀected by speciﬁed disorders and were not pregnant, and for whom we had at 
least two FEV1 and FVC measurements that did not vary by more than 200 mL. We divided the 
countries into seven socioeconomic and geographical regions: south Asia (India, Bangladesh, 
and Pakistan), east Asia (China), southeast Asia (Malaysia), sub-Saharan Africa (South  Africa 
and Zimbabwe), South America (Argentina, Brazil, Colombia, and Chile), the Middle East (Iran, 
United Arab Emirates, and Turkey), and North America or Europe (Canada, Sweden, and 
Poland). Data were analysed with non-linear regression to model height, age, sex, and 
region.  
Findings: 153 996 individuals were enrolled from 628 communities. Data from 38 517 
asymptomatic, healthy non-smokers (25 614 women; 12 903 men) were analysed. For all 
regions, lung function increased with height non-linearly, decreased with age, and was 
proportionately higher in men than women. The quantitative eﬀect of height, age, and sex on 
lung function diﬀered by region. Compared with North America or Europe, FEV1 adjusted for 
height, age, and sex was 31·3% (95% CI 30·8–31·8%) lower in south Asia, 24·2% (23·5–24·9%) 
lower in southeast Asia, 12·8% (12·4–13·4%) lower in east Asia, 20·9% (19·9–22·0%) lower in 
sub-Saharan Africa, 5·7% (5·1–6·4%) lower in South America, and 11·2% (10·6–11·8%) lower in 
the Middle East. We recorded similar but larger diﬀerences in FVC. The diﬀerences were not 
accounted for by variation in weight, urban versus rural location, and education level between 
regions.                                                                                                                                                                                              
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Interpretation: Lung function diﬀers substantially between regions of the world. These 
large diﬀerences are not explained by factors investigated in this study; the contribution of 
socioeconomic, genetic, and environmental investigated in this study; the contribution of 
socioeconomic, genetic, and environmental factors and their interactions with lung 
function and lung health need further clarification. 
 
Introduction 
The global rise in disease burden from chronic respiratory diseases1 means that more 
information is needed about global lung health, particularly factors that adversely aﬀect 
lung function.2 Diﬀerences in lung function between ethnic groups have previously been 
investigated, but generally within one country or region.3 The most widely reported 
comparisons of lung    function    (forced    expiratory    volume    in 1 s [FEV1] and 
forced vital capacity [FVC]) are between white  people  and   African   Americans   
(decrease of 10–15%4,5) and between white people and individuals of Asian origin 
(decrease of 6–12%6,7). Few data are available for other ethnic groups and populations 
in diﬀerent geographical regions with vastly diﬀerent socioeconomic and environmental 
exposures that could aﬀect lung function.8 
 
Our aim was to document the risk factors for chronic respiratory disease burden in adults 
globally. We deliberately oversampled countries of low to middle income, where the 
disease burden is high9 and expected to rise further; little information about lung function 
and lung health is available for these regions. We postulated that, after adjustment for height, 
age, and sex, substantial global diﬀerences in lung function would be recorded, which 
would be a result of the complex interactions between genes and environment for each 
region. These diﬀerences could contribute to the baseline population risk for chronic 
respiratory  disease and  the  global disparity in disease burden. 
 
Methods 
Study design and participants 
In the international, community-based prospective Population Rural Urban 
Epidemiology (PURE) study, we enrolled individuals aged 34–80 years from 628 urban 
and rural communities in 17 countries across five continents. Enrolment occurred 
between Jan 1, 2005, and Dec 31, 2009, except in Karnataka, India, where it began on Jan 
1, 2003. 
 
Details of the enumeration and recruitment methods are provided in the appendix and 
have been reported elsewhere.10 We used a multistage, convenience-sampled survey; 
countries and communities were chosen purposively in the first and second stages, and 
households or individuals were selected by random sampling in the third stage. We 
selected countries in different phases of epidemiological transition and where long-term 
followup was possible. The primary sample unit was the community. We selected a 
diverse sample of communities in each country purposefully, conveniently, or randomly 
(appendix), with stratification by urban or rural location.  
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In each community, we used a sampling framework to recruit a representative sample of 
households. In all countries of low to middle income, door-to-door visits were done by 
trained local staff. In high-income countries, information about the study was initially 
sent to selected households by post. Study staff subsequently made telephone calls to the 
selected households, inviting eligible representatives to a central clinic. For both 
approaches, at least three attempts to contact an individual in each household were made. 
Households were eligible if at least one member was aged 35–70 years and intended to 
stay at the address for a further 4 years. 
 
All eligible individuals in the selected households who provided written informed consent 
were enrolled. When an eligible household or individual refused to participate, 
demographic information and data about tobacco use, education, and history of 
cardiovascular disease were recorded in a non-responder form. 
 
The study was coordinated by the Population Health Research Institute (Hamilton, ON, 
Canada). The protocol was approved by the Hamilton Health Sciences Research Ethics 
Board and by the local ethics committee at each site. 
 
Procedures 
At a second household visit (countries of low and middle income) or during participants’ visit 
to a central clinic (high-income countries), local staﬀ recorded information about 
demography, medical diagnoses, ethnic origin, tobacco use history, and respiratory 
symptoms with interview-based questionnaires.11–14 Questionnaires were translated into 
the local language with a standardised protocol (appendix). During the second household 
visit in countries of low and middle income, an appointment was scheduled for physical 
measurements (including spirometry) and blood and urine tests. 
 
During this appointment, or at the visit to the central clinic in high-income countries, 
weight was measured on calibrated scales with as little clothing as possible and without 
shoes. Height was measured with a Frankfort plane against a ﬂat wall, with heels together. 
 
A portable device (MicroGP, MicroMedical, Chatham, IL, USA), chosen for its aﬀordability 
and ease of use, was used for spirometry measurements, but did not generate ﬂow-volume 
loops (FVLs). Each participant attempted up to six prebronchodilator forced expiratory 
manoeuvres while standing and wearing a nose clip. Measurements of maximum eﬀort and 
forced exhalation for at least 6 s were taken. The three highest measurements of FEV1, 
FVC, and peak expiratory ﬂow (PEF) were recorded. Spirometer calibration with a 3 L 
syringe was done monthly and when thought necessary by local staﬀ (eg, before use in 
extreme temperatures). 
 
Data quality was maintained in three ways. First, key staﬀ from each centre attended regional 
training sessions, in which standardised protocols and materials were used. These key staﬀ in 
turn trained local staﬀ. Local staﬀ were tested on mock participants and certiﬁed. Retraining 
and certiﬁcation occurred every 18 months. Second, prospective validation was done in 11 
countries (Brazil, Canada, China, Colombia, India, Iran, Malaysia, South Africa, Sweden, 
Turkey, and United Arab Emirates) where study centres had access to pulmonary function 
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laboratories. The ﬁrst 30 participants who attended follow-up visits at the study centre with 
the highest number of participants in each country were included in prospective validation. 
Con- current measurements with PURE methods (as used in the ﬁeld) and in a pulmonary 
function laboratory (appendix) were obtained for these participants. In South Africa, 
spirograms were produced at baseline, meaning that FVL measurements were available. 
 
 
 
Third, data were entered electronically into a  customised database programmed with 
range and consistency checks and transmitted to the coordinating centre. Cases with 
missing values, transcription errors, or implausible data that could not be reconciled were 
removed. 
 
For analyses, we selected participants with at least two measurements of FEV1 and FVC 
with maximum eﬀort, without cough and within 200 mL variability for analysis. 
Individuals for whom the highest FEV1 divided by the highest FVC was 0·95 or higher, 
or less than 0·66, or for whom the highest PEF divided by the highest FEV1 was less 
than 1·5 were deemed to have made less than maximum eﬀort and were excluded. We 
derived these cutoﬀs from centres with high-quality data for acceptable maximum 
expiratory eﬀort and forced expiratory time. We removed outliers that had an eﬀect (with 
Cook’s D statistic). Additionally, we excluded participants younger than 34 years and 
older than 80 years, and those shorter than 130 cm or taller than 190 cm from analyses 
because of small numbers. Further exclusion criteria were tobacco use of more than  5  
pack-years,  chronic  obstructive  pulmonary disease (COPD), asthma, tuberculosis, 
cancer, pregnancy, regular use of respiratory medications, symptoms of breathlessness 
with usual activity in the previous 6 months, wheeze, haemoptysis, morning cough, 
chest tightness, or daily productive cough for 3 months a year for at least 2 years. 
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According to the World Bank Classiﬁcation15 available when the study began, three of the 
countries where data were gathered had high income status and 14 low or middle 
income status. With this information, we divided the 17 countries into seven socioeconomic 
and geographical regions: south Asia (India, Bangladesh, and Pakistan), east Asia (China), 
southeast Asia (Malaysia), sub-Saharan Africa (South Africa and Zimbabwe), South 
America (Argentina, Brazil, Colombia, and Chile), the Middle East (Iran, United Arab 
Emirates, and Turkey), and North America or Europe (Canada, Sweden, and Poland). 
 
Statistical analysis 
Details of model derivation and validation are provided in the appendix. A non-linear 
multiplicative regression with no  intercept   (Gauss-Newton  method)  was   the  most 
biologically plausible, best ﬁtting, and parsimonious model. 
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In the base model, FEV1 (or FVC) was expressed as a function of height, which is the most 
important explanatory variable. We estimated the eﬀect of age, sex, and region 
proportionally to height (or calculated the percentage change by multiplying by 100). This 
proportional scaling to height avoided the large change in absolute lung function recorded in 
tall individuals compared with short individuals even though the proportional change is 
the same. We coded age (34 years coded 0; subsequent ages coded consecutively), sex 
(male coded 0; female 1), and region (North America or Europe coded 0; Middle East 1; 
South  America  2;  sub-Saharan  Africa  3;  east  Asia  4; southeast Asia 5; south Asia 6). 
 
We examined model ﬁt by two methods (appendix). First, we used internal validation, 
deriving the model from a randomly selected subpopulation (80%) and examining 
model ﬁt on the remaining 20%. This method showed no signiﬁcant diﬀerence between 
the observed and predicted values. Second, we used face validity by showing that the 
standardised lung function values (ie, percentage of predicted) in participants with 
COPD, asthma, tuberculosis, and heart disease showed the expected pattern of 
impairment in these disorders. 
 
We deemed a p value of less than 0·001 to be signiﬁcant. All analyses were done with 
Statistica (version 10). 
 
Role of the funding source 
The sponsors of the study had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. MD and SY had full access to all the data in 
the study and had ﬁnal responsibility for the decision to submit for publication. 
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Results 
153 996 individuals were enrolled from the 628 communities (ﬁgure 1). The countries with the 
highest numbers of participants were China and India (table 1). The proportion of 
unacceptable data was highest for South America and lowest for North America or Europe 
(table 2). The large amount of unacceptable data was not associated with low unadjusted 
lung function measurements (table 2). Healthy individuals excluded because of 
unacceptable data had similar baseline characteristics to individuals included in the study, 
conﬁrming that the analysed population was a representative sample (appendix). Other 
common reasons for exclusion were respiratory symptoms, speciﬁed disorders (eg, asthma, 
HIV, or malaria) or pregnancy, and tobacco smoking (table 2). 
 
 
 
38 517 asymptomatic, healthy non-smokers made up the ﬁnal population (ﬁgure 1). More 
women than men were included overall and in each region (tables 2, 3). More than 80% of 
participants in each region were from the ethnic group in the majority, except in the 
Middle East (table 3). Included men were taller than women, and had higher unadjusted 
FEV1 and FVC across all regions (table 3). Participants from North America or Europe 
were the tallest, and had the highest unadjusted lung function (table 3). 
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501 individuals participated in prospective validation. The diﬀerence between FEV1 
measurements in the ﬁeld and the laboratory was small (≤200 mL) for all regions 
(appendix), suggesting that ﬁeld measurements of FEV1 were valid. Diﬀerences in FVC 
measurements of greater than 200 mL were recorded in South America, the Middle 
East, and east Asia (appendix). The variability of the diﬀerences in FEV1 and FVC was 
greatest for the Middle East, east Asia, and south Asia, suggesting decreased agreement. 
Retrospective analysis of FVL measurements for 30 participants in South Africa 
showed than 20 (67%) of 30 had acceptable FVL measurements as deﬁned by American 
Thoracic Society standards. 
 
The fitted base model was FEV1 or   FVC=(a × heightb) × (1+c × age) × (1+d × male sex) × (1 
+ e × region). For all regions, FEV1 increased with height and decreased with age for both 
men and women (ﬁgure 2). FEV1 and FVC related to height in a non-linear fashion (tables 
4, 5). The mean cross-sectional reduction in FEV1 per year after age 34 years is 
proportional to height (table 4). The increase in FEV1 conferred by male sex was almost 
19% (table 4). Compared with North America or Europe, all other regions had proportionally 
lower adjusted FEV1 and FVC (ﬁgure 3; tables 4, 5). The greatest diﬀerences were 
reported for south Asia, southeast Asia, and sub-Saharan Africa (ﬁgure 3; tables 4, 5). 
 
The quantitative eﬀect of height, age, and sex on lung function diﬀered by region (table 6). 
Furthermore, the proportion of explained variance (pseudo-R²) was highest for North  
America  or  Europe  and the  Middle  East (table 6), suggesting that other predictors of lung 
function are not covered by this model for the other regions. 
 
To assess for potential confounders of this regional diﬀerence, we added other covariates, 
such as education level, urban versus rural location, and weight to the base model (tables 4, 5). 
Although these variables signiﬁcantly contributed to lung function, they had little eﬀect on 
regional lung function diﬀerences and therefore were not confounders (tables 4, 5). 
Furthermore, the ﬁt of the model did not improve (no increase in pseudo-R²; tables 4, 5). 
 
The ratio between FEV1 and FVC was inversely correlated to height and age, but had no 
association with sex (ﬁgure 4). The ratio diﬀered by region for any height, age, and sex (ﬁgure 
4). 
 
Discussion 
To our knowledge, we have provided the ﬁrst large-scale assessment of global variation in 
lung function in asymptomatic non-smokers in diﬀerent regions of the world (panel). 
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We reported a signiﬁcant and substantial diﬀerence in lung function between regions, with 
North America and Europe having the highest lung function and south Asia the lowest. 
These diﬀerences are not explained by variation in distribution of height, age, sex, weight, 
urban versus rural settings, or education levels. 
 
Lung function diﬀerences between healthy populations across the world are expected and 
are attributed to ﬁxed anthropometric diﬀerences that are believed to be genetic.3 
However, this belief is not supported by studies showing greater genetic variation within 
than between populations,19 and that a large proportion of reported diﬀerences in lung 
function between populations is not explained by variation in genetic ancestry  
markers.20     Alternatively,  some  evidence suggests that anthropometric features and 
lung function can change with time and place, driven by socioeconomic and 
https://repository.uwc.ac.za/
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environmental changes.16–18,21 US- born individuals of Indian and Japanese origin 
are taller and have larger lung volumes than individuals born in the Indian 
subcontinent16 and Japan17 who subsequently moved to the USA. Moreover, children of 
Indian origin aged 11–13 years who are born in the UK have longer leg length (a marker of 
good nutrition early in life) than do those who have recently moved to the UK.18 
Additionally, those born in the UK have body dimensions that resemble those of 
Europeans.21 Similarly, trends in increasing somatic growth and lung capacity in 
successive cohorts within a country that parallel improvements in living standards with 
time have been documented.22,23 
 
However, such changing characteristics have not been shown in European 
populations.24,25 We speculated that the higher socioeconomic status and living 
standards of populations of European descent are similar and stable across time and 
place, allowing maximum lung function to be attained and leaving little room for 
further improvement or variation. In support of this hypothesis, we recorded that the 
usual predictors (height, age, and sex) explained a higher proportion of lung function 
variability in North America or Europe and the Middle East, where mainly high- income 
and urban-dominated countries were included, than elsewhere. Regions of low or middle 
income are more contextually diverse than those of high income, with varying conditions 
that can adversely aﬀect lung function, leading to a greater unexplained variance in lung 
function. 
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Reported adverse conditions include early life exposures to outdoor26 and indoor air 
pollution,27 second-hand cigarette smoke,28 respiratory infections,29 nutritional 
factors,30 overcrowding,31 and low birthweight.32 Failure to adjust for socioeconomic 
status (and the associated risk factors) has been proposed to confound the relation 
between ethnic origin or regions and low lung function.3,8 However, adjustment for 
weight (for body dimension), urban versus rural location (physical environment), and 
education level (socioeconomic status) had little eﬀect on the lung function gradient 
across regions in our study. This ﬁnding suggests that the situation is far more 
complex than previously thought, that the regional lung function diﬀerence is a result 
https://repository.uwc.ac.za/
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of wide-ranging eﬀects of known and unknown factors, and that the interaction between 
genes and the environment cannot be fully adjusted for within one model. 
 
 
 
 
Our ﬁndings have important public health implications. The large diﬀerences in lung function 
between regions, if partly driven by the disadvantaged environment in some regions, raise 
concerns about whether a diﬀerence should be expected, particularly when the same 
conditions that predict low lung function can adversely aﬀect general health and 
mortality.33 This overlap could partly explain the well known epidemiological link 
between low lung function and increased mortality.34 It also puts into question the use of 
ethnic-speciﬁc values of lung function, because they could lead to an underestimation of 
the true mortality risk in non-white populations.35 Our ﬁndings draw attention to the need 
for improved understanding of the social and gene–environment factors that aﬀect lung 
function and their prognostic implications. 
 
Several aspects and limitations of our study need further discussion. First, we took a 
sociogeographic approach to the comparison of lung function, because it will set the 
framework for future analyses of the contextual mechanisms contributing to lung 
health inequalities across regions. However, this cross-sectional analysis cannot delineate 
the eﬀects of genes versus contextual factors on lung function. As lung function in regions 
undergoing socioenvironmental changes driven by economic growth is tracked, the 
contextual and genetic eﬀect can be better deﬁned. 
 
Second, our statistical approach was based on biologically plausible principles combined 
with robust regression modelling that can handle data that do not meet linear model 
assumptions (non-linear associations between predictors and lung function, and non-constant 
variability). It also allows for the complex interactions between the explanatory variables of 
lung function. This scaling of diﬀerences in lung function relative to North America or 
Europe is similar to an approach endorsed by the American Thoracic Society and the 
European Respiratory Society.25 
 
Third, the scale of our study, most of which was done in resource-challenged and remote 
areas, meant that use of advanced, costly spirometers that can provide FVL was 
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impractical. Therefore, we were unable to retrospectively verify data from individuals and 
instead used other criteria to validate our data epidemiologically, such as selection of 
recordings that meet criteria of the American Thoracic Society or European Respiratory 
Society for maximum eﬀort (repeatability, without cough, and >6 s), comparisons of 
reported and predicted values for small diﬀerences (internal validity), establishment of 
the expected changes in spirometry values for individuals with various medical disorders 
(face validity), and investigation of agreement between ﬁeld and pulmonary laboratory 
measurements in 501 participants from 11 countries (external validity). Furthermore, 
our ﬁndings are in keeping with other studies that have shown that individuals from 
North America and Europe have the highest lung function but lowest ratio of FEV1 to FVC 
compared with some other ethnic or geographical groups.4,25 Similarly, the key 
questionnaires (demographics and tobacco-use history) were taken from large 
international epidemiological studies13,14 that have been translated and applied to 
regions or countries that are similar to those included in our study. Information about 
symptoms was internally validated by comparison of lung function diﬀerences between 
participants with and without symptoms. Moreover, all centres and operators were 
trained in the same way on the same equipment and questionnaires. Together with the 
large sample size and numbers  of  included  centres  in  each  region,  the validation will 
mean measurement errors (if present) are random and therefore would tend to 
underestimate the true diﬀerences between regions. Collectively, these considerations give 
us conﬁdence about the validity of the group data generated by our study. 
 
Finally, postbronchodilator measurements were not feasible at baseline data collection, in 
view of the scale of our study, but are recommended by international guidelines for the 
diagnosis of airway diseases.36 However, we used the same inclusion and exclusion 
criteria and prebronchodilator values as in other studies that examined lung function 
diﬀerences between ethnic groups, meaning that our conclusions can be compared with 
reported data.4,6,25 Although diﬀerences between the prebronchodilator and 
postbronchodilator values have since been shown to be small in healthy European 
populations,37 no similar information about populations outside of this region is available. 
These diﬀerences will be investigated in a subgroup of PURE in the next phase of data 
collection to address the issue of subclinical diseases in regions of low and middle income. 
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